ProMIS Neurosciences Inc (NAS:PMN)

Q2 2026 ProMIS Neurosciences Inc Earnings Call Transcript

Aug 13, 2026 / 08:30 PM GMT

Release Date Price: $14.87 (+2.52%)

Transcript 8-K10-Q

Key Points

Positve

Reported zero cases of ARIA-E across all genotypes, including high-risk APOE4 carriers, in the Phase 1b PRECISE-AD trial.
Blinded interim biomarker data showed directionally consistent declines in plasma p-tau217 and CSF MTBR tau243, suggesting target engagement.
Strong cash position of $53.4 million, sufficient to fund operations through 2027, covering the anticipated 12-month top-line readout.
Pipeline advancement with PMN267 (ALS) and PMN442 (synucleinopathies) progressing toward IND-enabling studies.
Positive KOL and investor reception to interim data, with plans for a potential single registration study and subcutaneous formulation development.

Negative

Interim data are blinded and exploratory, not a determination of clinical efficacy.
Biomarker results are pooled across drug and placebo groups, limiting interpretation of a definitive drug effect.
No unblinded efficacy data on cognitive outcomes until the 12-month readout in Q1 2027.
Increased net cash used in operating activities ($22.8 million for six months) reflects higher clinical spending, with net loss widening.
Subcutaneous formulation development is early-stage, with no clarity on how it will integrate into the registration study.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PMN.OQ - ProMIS Neurosciences Inc
Q2 2026 ProMIS Neurosciences Inc Earnings Call
Aug 13, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, and welcome to the ProMist Neurosciences Second Quarter 2026 Financial Results and Business Update Conference Call. All participants will be in a listen-only mode. Instructions for the question-and-answer session will be given following the pre-recorded prepared remarks. As a reminder, this conference is being recorded.

I would now just turn the call over to Carrie Pierce, Vice President, Investor Relations and External Affairs at Promise Neurosciences. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.